Lipopolysaccharide and Coagulation Factor XII: Biophysics of Contact Activation in Infection
Seminars in Thrombosis and Hemostasis · 01.09.2026 · 52 (06) · 683-691
DOI: 10.1055/a-2716-6782 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Seminars in Thrombosis and Hemostasis, erschienen am 01.09.2026. Verfasst von André L Lira und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, Oregon Health and Science University, Portland, Oregon, United States. Hauptthemen laut MEDLINE: Lipopolysaccharides, Factor XII. Die Arbeit nennt 105 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, Institute of Allergy and Infectious Diseases, NHLBI NIH HHS.
Abstract (Originalsprache)
Lipopolysaccharide (LPS), a key component of the outer membrane of Gram-negative bacteria, is well-known for its role in triggering inflammation via innate immune receptors. However, evidence suggests that LPS can influence coagulation, in part through activation of the contact pathway. Recent studies from our group and others demonstrate that the supramolecular organization and physicochemical properties of LPS—such as aggregate size, surface charge, and chemotype—critically determine the ability of LPS to activate coagulation factor XII (FXII). While monomeric LPS can modulate FXII activity, only aggregated forms of LPS (e.g., micelles) function as a procoagulant surface, initiating contact activation. This review synthesizes current knowledge on LPS structural heterogeneity and explores how the biophysical properties of LPS govern supramolecular assembly in aqueous environments, ultimately dictating interactions with the contact activation pathway. We further discuss the possible mechanisms by which LPS-driven FXII activation contributes to thromboinflammatory disorders, including disseminated intravascular coagulation and sepsis-associated vascular leakage. Finally, we highlight novel therapeutic strategies—from FXIIa inhibitors to molecules that disrupt LPS supramolecular structures—as potential interventions to mitigate coagulation-driven pathology during bacterial infections. These insights not only reflect our growing understanding of infection-associated thrombosis but may also pave the way for targeted therapies in sepsis and other thromboinflammatory conditions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Engineering, Oregon Health and Science University, Portland, Oregon, United States.
- Division of Hematology and Medical Oncology, School of Medicine, Oregon Health and Science University, Portland, Oregon, United States.
Förderung
- NIAID NIH HHS
- Institute of Allergy and Infectious Diseases
- NHLBI NIH HHS
- National Institutes of Health, National Heart, Lung, and Blood Institute
Zitieren
APA
Lira, A. L., Drew, K. C., Puy, C., Shatzel, J. J., & McCarty, O. J. T. (2026). Lipopolysaccharide and Coagulation Factor XII: Biophysics of Contact Activation in Infection. Seminars in Thrombosis and Hemostasis, 52(06), 683-691. https://doi.org/10.1055/a-2716-6782
Vancouver
Lira AL, Drew KC, Puy C, Shatzel JJ, McCarty OJT. Lipopolysaccharide and Coagulation Factor XII: Biophysics of Contact Activation in Infection. Seminars in Thrombosis and Hemostasis. 2026;52(06):683-691. doi:10.1055/a-2716-6782
BibTeX
@article{Lira2026,
author = {Lira, André L and Drew, Katelyn C and Puy, Cristina and Shatzel, Joseph J and McCarty, Owen J T},
title = {Lipopolysaccharide and Coagulation Factor XII: Biophysics of Contact Activation in Infection},
journal = {Seminars in Thrombosis and Hemostasis},
year = {2026},
volume = {52},
number = {06},
pages = {683--691},
doi = {10.1055/a-2716-6782}
}
EUVIMED